Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Bayer is now going to conduct Phase 3 clinical trials for obstructive HCM in Japan, while Cytokinetics will expand its ongoing ACACIA-HCM and CEDAR-HCM trials into Japan.
XPeng forecasts quarterly revenue above estimates
XPeng expects fourth quarter revenue between 15.3 billion yuan and 16.2 billion yuan, compared with analysts' average estimate of 14.77 billion yuan, according to data compiled by LSEG. Revenue for ...
Indian news agency ANI sues OpenAI for unsanctioned content use in AI training
NEW DELHI (Reuters) - Indian news agency ANI has sued OpenAI in a New Delhi court, accusing the ChatGPT creator of using its published content without permission to help train the artificial ...